Goldman Sachs
UTHR icon

Goldman Sachs’s United Therapeutics UTHR Stock Holding History

Goldman Sachs’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$1.79M – 6533
2021
Q2 		$1.79M Buy
+10,000
New +$1.9M ﹤0.01% 4306
2020
Q2 		– Sell
-25,000
Closed -$2.37M – 5495
2020
Q1 		$2.37M Buy
25,000
+5,200
+26% +$494K ﹤0.01% 3177
2019
Q4 		$1.74M Buy
+19,800
New +$1.74M ﹤0.01% 3743
2018
Q1 		– Sell
-2,900
Closed -$429K – 6419
2017
Q4 		$429K Sell
2,900
-18,500
-86% -$2.35M ﹤0.01% 4944
2017
Q3 		$2.51M Buy
21,400
+14,300
+201% +$1.83M ﹤0.01% 3777
2017
Q2 		$921K Buy
7,100
+2,800
+65% +$349K ﹤0.01% 4544
2017
Q1 		$582K Sell
4,300
-4,300
-50% -$651K ﹤0.01% 4868
2016
Q4 		$1.23M Sell
8,600
-400
-4% -$51.1K ﹤0.01% 4268
2016
Q3 		$1.06M Buy
9,000
+2,600
+41% +$312K ﹤0.01% 4348
2016
Q2 		$678K Sell
6,400
-23,100
-78% -$2.58M ﹤0.01% 4569
2016
Q1 		$3.29M Sell
29,500
-6,700
-19% -$848K ﹤0.01% 3058
2015
Q4 		$5.67M Buy
36,200
+16,700
+86% +$2.43M ﹤0.01% 2712
2015
Q3 		$2.56M Sell
19,500
-21,600
-53% -$3.46M ﹤0.01% 3547
2015
Q2 		$7.15M Buy
41,100
+11,900
+41% +$2.14M ﹤0.01% 2632
2015
Q1 		$5.04M Buy
29,200
+21,100
+260% +$3.22M ﹤0.01% 2893
2014
Q4 		$1.05M Sell
8,100
-56,700
-88% -$7.31M ﹤0.01% 4514
2014
Q3 		$8.34M Buy
64,800
+29,000
+81% +$2.99M ﹤0.01% 2522
2014
Q2 		$3.17M Buy
35,800
+21,200
+145% +$2.04M ﹤0.01% 3515
2014
Q1 		$1.37M Buy
14,600
+6,400
+78% +$655K ﹤0.01% 4354
2013
Q4 		$927K Buy
8,200
+1,500
+22% +$135K ﹤0.01% 4802
2013
Q3 		$528K Sell
6,700
-4,000
-37% -$292K ﹤0.01% 5125
2013
Q2 		$704K Buy
+10,700
New +$689K ﹤0.01% 4671

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Goldman Sachs's UTHR Position: Q1 2026 in Review

Goldman Sachs increased its United Therapeutics (UTHR) stake by 3.3% in Q1 2026, buying an estimated $1.82M and bringing the position to 114,419 shares worth $67.8M. The position accounts for 0.01% of the portfolio, ranked #1328.

Goldman Sachs first reported a position in UTHR in Q2 2013 and has held it in 52 quarters since. The position peaked at $204M in Q2 2017. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Goldman Sachs held 114,419 shares of United Therapeutics worth $67.8M as of Q1 2026.
  • Goldman Sachs bought 3,645 United Therapeutics shares in Q1 2026, an estimated $1.82M.
  • United Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1328 holding.
  • Goldman Sachs first reported a position in United Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Goldman Sachs's United Therapeutics position peaked at $204M in Q2 2017.
  • 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.